What’s Propelling Vbi Vaccines Inc – Ordinary Shares (NASDAQ:VBIV) After Lower Shorts Reported?

March 14, 2018 - By Dolores Ford

 What’s Propelling Vbi Vaccines Inc   Ordinary Shares (NASDAQ:VBIV) After Lower Shorts Reported?

The stock of Vbi Vaccines Inc – Ordinary Shares (NASDAQ:VBIV) registered a decrease of 50.26% in short interest. VBIV’s total short interest was 423,000 shares in March as published by FINRA. Its down 50.26% from 850,400 shares, reported previously. With 96,000 shares average volume, it will take short sellers 4 days to cover their VBIV’s short positions. The short interest to Vbi Vaccines Inc – Ordinary Shares’s float is 1.1%.

The stock decreased 1.27% or $0.05 during the last trading session, reaching $3.89. About 65,576 shares traded. VBI Vaccines Inc. (NASDAQ:VBIV) has risen 7.87% since March 14, 2017 and is uptrending. It has underperformed by 8.83% the S&P500.

VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company has market cap of $156.49 million. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. It currently has negative earnings. The firm also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants.

VBI Vaccines Inc. (NASDAQ:VBIV) Ratings Coverage

Among 4 analysts covering VBI Vaccines (NASDAQ:VBIV), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. VBI Vaccines had 6 analyst reports since July 26, 2016 according to SRatingsIntel. The firm earned “Buy” rating on Monday, October 10 by Laidlaw. BMO Capital Markets initiated VBI Vaccines Inc. (NASDAQ:VBIV) on Wednesday, November 15 with “Buy” rating. The firm has “Buy” rating given on Wednesday, November 1 by Canaccord Genuity. The firm earned “Buy” rating on Tuesday, July 26 by Ladenburg Thalmann.

More notable recent VBI Vaccines Inc. (NASDAQ:VBIV) news were published by: Benzinga.com which released: “VBI Vaccines Could Nearly Triple In Value On New Drug Launches, According To BMO” on November 15, 2017, also Globenewswire.com with their article: “VBI Vaccines Announces Voluntary Delisting from the Toronto Stock Exchange” published on March 12, 2018, Globenewswire.com published: “VBI Vaccines Announces Closing of Public Offering and Concurrent Registered …” on October 31, 2017. More interesting news about VBI Vaccines Inc. (NASDAQ:VBIV) were released by: Benzinga.com and their article: “Meet VBI Vaccines, The Biotech Up 100% In 2017” published on March 07, 2017 as well as Globenewswire.com‘s news article titled: “VBI Vaccines Announces Proposed Concurrent Public Offering and Registered …” with publication date: October 25, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: